Evgen Pharma Plc (LON:EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces that it has received notice to exercise options over 837,600 ordinary shares in the Company.
The options were granted under individual option agreements and have exercise prices of 5 pence per share in respect of 628,000 options and 0.875 pence per share in respect of 209,600 options. Accordingly, the Company has issued and allotted 837,600 new ordinary shares of 0.25 pence each (“New Ordinary Shares”). The New Ordinary Shares rank pari passu with the Company’s existing issued ordinary shares. Application has been made to admit the New Ordinary Shares to trading on AIM and dealings in these shares are expected to commence at 8.00 a.m. on 6 September 2017.
There are no shares held in treasury, therefore following the admission of the New Ordinary Shares the total number of voting rights in Evgen Pharma plc will be 74,110,191. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest under the Disclosure and Transparency Rules.